Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HBV-MPL vaccine · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | ACTIVE_COMPARATOR | - |
| Group C | EXPERIMENTAL | - |
| Group D | EXPERIMENTAL | - |
| Group E | EXPERIMENTAL | - |
| Group F | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| HBV-MPL vaccine | BIOLOGICAL | 3-dose intramuscular injection |
| Engerix™-B | BIOLOGICAL | 3-dose intramuscular injection |
Inclusion Criteria: * Age: 50 to 70 years old. * Good physical condition as established by clinical examination and history taking at the time of entry. * Female participants who are at risk to become pregnant will be on a contraceptive programme if necessary during the study period. * Written info...
HBV-MPL vaccine is an investigational vaccine being developed for the prevention of Hepatitis B. It is designed to be given to adults, with clinical trials evaluating its use in healthy volunteers aged 18 years and older. The vaccine is currently in Phase 3 clinical development.
HBV-MPL vaccine is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. GSK is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in adult populations.
HBV-MPL vaccine is in Phase 3 clinical development. It has completed three clinical trials, including one Phase 3 study and two Phase 2 studies. The vaccine is investigational and has not been approved by regulatory authorities.
HBV-MPL vaccine has completed three clinical trials. The Phase 3 trial, NCT00696891, compared the vaccine with Engerix-B in adults aged 50 years and older. Two Phase 2 trials, NCT00698555 and NCT00698906, evaluated different formulations in adults aged 18-40 and 19-40 years, respectively.
No, HBV-MPL vaccine is not the same as Engerix-B. Engerix-B is a comparator vaccine used in clinical trials to evaluate the safety and immunogenicity of HBV-MPL vaccine. The trials were designed to compare HBV-MPL vaccine with Engerix-B in adult populations.